Sector News

Some reasons why Pfizer won’t bid for AstraZeneca again

November 19, 2014
Life sciences
Neil Woodford, the fund manager, sees a 50/50 likelihood that Pfizer will take another pop at AstraZeneca once the six-month “hands off” period expires in a week’s time. That ratio feels too high.
 
First, the Pfizer-related reasons. The US pharmaceuticals group offered £55 per AstraZeneca share in the spring but may have been relying on its tax “inversion” plans to make its numbers stack up. Such tax flips have not been outlawed by the US administration (just made harder) but any new offer might have to structured more like a merger than a takeover to meet the revised rules.
 
An all-share deal in which AstraZeneca’s investors were offered 40% ownership of a new company might qualify, think investment bankers. But that would currently value the UK company at £60-ish. It would be tricky for Pfizer to explain to its own shareholders why it is suddenly prepared to pay so much more.
 
Pfizer’s management may also be looking in other directions. On Monday the US firm paid $850m (£544m) for rights to a cancer immunotherapy drug being developed by Merck. The sum is peanuts for a company the size of Pfizer. But the deal would still be odd if a fresh assault on AstraZeneca, whose development pipeline is loaded with potential cancer treatments, is being contemplated.
 
Then there’s the career-risk in making another tilt at AstraZeneca. Pfizer boss Ian Read’s credibility would be shattered if he failed twice to pull off the same mega-deal. Nor can Read know how intense the UK political heat would be this time – except that for the next few months, in the run-up to a general election, it would be red-hot.
 
Then there are the AstraZeneca-related reasons. Tuesday’s detailed presentation to investors was not a just-in-case defence document, but it might as well as have been. There were few surprises but chief executive Pascal Soriot stuck to his big targets – a return to sales growth in 2017 and a jump in revenues of 75% to $45bn by 2023. Some eight-to-10 new drug approvals are expected next year; if those arrive on cue, the momentum should still be with AstraZeneca.
 
As Woodford says, the value of a drug pipeline is “impossibly difficult to model with precision.” Judgment is required and his opinion is that “the long-term value that lies in AstraZeneca’s pipeline remains overwhelmingly positive.”
 
It is conceivable that Pfizer might reach the same conclusion, reflect that it got close last time, and have another crack at a takeover. Anything is possible in a pharma-land still gripped by deal-fever.
 
In the US, Allergan, the Botox company, this week agreed to sell itself to Actavis for $66bn, or roughly double its stock market valuation at the start of this year. If that’s an accurate yardstick of value, AstraZeneca might be considered a snip at £60 a share or more, even against the current price of £46.85.
 
On balance, though, it’s odds against a repeat attempt. Woodford says 50%, but 20%, at most, feels nearer the mark.
 
By Nils Pratley
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”